Fate Therapeutics Inc FATE:NASDAQ

Last Price$15.61NASDAQ Previous Close - Last Trade as of 4:00PM ET 4/17/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$15.25 (3)
Ask (Size)$16.50 (2)
Day Low / HighN/A - N/A
Volume899.5 K
  • Latest Stories
  • Commentary and Analysis
Fate Therapeutics Says First Patient Treated With Cancer Therapy Completes Initial Safety Assessment
8:28AM ET 4/02/2019 MT Newswires

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Tuesday that the first patient treated with its cancer drug FT500...

Analyst Actions: SVB Leerink Starts Fate Therapeutics At Outperform, With $20 Price Target
7:59AM ET 3/28/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $20. Price: 16.71, Change: -0.10, Percent Change: -0.59...

Fate Therapeutics Reports Mixed Q4; Shares Slip 2.3% After Hours
4:32PM ET 3/05/2019 MT Newswires

Fate Therapeutics (FATE) reported a net loss of $0.25 per share for Q4 from a loss of $0.29 a year earlier, but that was wider than the consensus on...

Earnings Reaction History: FATE THERAPEUTC, 60.0% Follow-Through Indicator, 6.0% Sensitive
2:46PM ET 3/05/2019 MT Newswires

Expected Earnings Release: 03/05/2019, After-hours Avg. Extended-Hours Dollar Volume: $356,938 FATE THERAPEUTC (FATE) is due to issue its quarterly...

Analyst Actions: Wedbush Lifts Fate Therapeutics PT to $21 From $19; Maintains Outperform Rating
12:42PM ET 2/11/2019 MT Newswires

Wedbush said Monday it has raised Fate Therapeutics (FATE) price target to $21 from $19, while reiterating its outperform rating. According to the broker,...

Fate Therapeutics Wins FDA Clearance of IND Application for FT516; Shares Jump Pre-Bell
9:30AM ET 2/06/2019 MT Newswires

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Wednesday that the FDA has allowed its "investigational new drug"...

Continued Level of Significant Insider Selling at Fate Therapeutics (FATE)
10:16PM ET 2/01/2019 MT Newswires

An insider sold 97,500 shares of Fate Therapeutics having a market value of approximately $1,380,795 today, as disclosed in a form 4 document filed with...

Insider Trends: Insider 90-Day Selling Trend Extended at Fate Therapeutics
5:11PM ET 2/01/2019 MT Newswires

Dr Amir Nashat, Director, sold 53,017 shares in Fate Therapeutics (FATE) for $750,959 on Jan 30, 2019. Dr Nashat, following the transactions outlined in...

Insider Trends: Fate Therapeutics Insider Extends 90-Day Selling Trend
6:03PM ET 1/31/2019 MT Newswires

Dr Amir Nashat, Director, on Jan 29, 2019, sold 97,500 shares in Fate Therapeutics (FATE) for $1,380,795. Subsequent to the Form 4 filing with the SEC, Dr...

Significant Insider Selling in Shares of Fate Therapeutics (FATE) Continues
10:16PM ET 1/30/2019 MT Newswires

A SEC filing today disclosed a substantial insider sale of Fate Therapeutics shares as -- Dr Amir Nashat, Director -- disposed of 90,000 shares in the...